Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

Phase 2

Recruiting

• Conditions: Neuroblastoma
• Interventions: Drug: Arsenic trioxide; Drug: MAPK inhibitors; Drug: Chemotherapy

• Registration Number: NCT06933394
• Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Brief Summary

This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of the combination therapy involving arsenic trioxide, MAPK inhibitors, and chemotherapy for stage 4/M neuroblastoma.

Detailed Description

Neuroblastoma (NB) is the most common extracranial solid tumor in children. Since 2018, we have led a prospective, nationwide multicenter collaborative clinical study on arsenic trioxide(ATO) combined with chemotherapy for 4/M stage NB (NCT03503864).The results indicate that the objective response rate (ORR) and complete remission rate (CRR) at the end of induction (EOI) for the ATO-combined chemotherapy regimen are significantly higher than those of the commonly used NB regimens in China, as well as the internationally recognized rCOJEC and MSKCC-N5 regimens. Additionally, the ATO regimen demonstrates a lower incidence of toxic side effects, providing favorable conditions for subsequent consolidation therapy and contributing to the long-term survival of High-risk neuroblastoma(HR-NB) patients. However, in clinical practice, we found that some children responded poorly to ATO combined induction chemotherapy, with lesions persisting or progressing and recurring, gradually developing into refractory cases during induction chemotherapy. Studies show that primary/acquired resistance in NB is related to the high-frequency clonal diversity that gradually emerges with chemotherapy.

With the advancement of precision medicine technology and in-depth research on signaling pathways, we found the RAS-MAPK signaling pathway plays an important role in the regulation of cell proliferation and differentiation, and this pathway is abnormally activated in various tumors. Literature reports that 78% of refractory/recurrent NB have activating mutations in the RAS-MAPK pathway, suggesting a close association between this pathway and refractory/recurrent NB. In addition, in some tumor cell lines, ATO can cause upregulation of the MAPK pathway, which may be the reason for the poor efficacy of ATO in some HR-NB children and suggests the necessity of combining MAPK inhibitors in ATO-containing induction chemotherapy regimens. Studies have shown that in APL cell line NB4 and APL primary cells, MAPK (MEK) inhibitors (PD98059 and PD184352) enhance apoptosis in ATO-treated cells by inhibiting downstream ERK1/2 and Bad phosphorylation, indicating that combining ATO with MAPK inhibitors can further improve efficacy.

Clinical studies show that single-agent MAPK inhibitors often have poor efficacy in the treatment of advanced or refractory tumors. Studies have found that in ALK-dependent RAS-MAPK mutant NB cell lines, MAPK inhibitors can activate the pro-cancer PI3K-AKT pathway through the mTORC2 complex-related subunit SIN1, and thus the MAPK inhibitor trametinib cannot inhibit the growth of ALK-dependent NB in mouse models. Previous studies have found that ATO can downregulate the PI3K-AKT pathway in various tumors, and we have found through non-label quantitative proteomics technology that ATO treatment of NB cell line SK-N-BE(2) can also cause downregulation of this pathway, and studies have shown that ATO can inhibit the activity of the mTORC2 complex in this pathway. In summary, we propose combining ATO with MAPK inhibitors, with the aim of using MAPK inhibitors to counteract the adverse effects of ATO activating the MAPK pathway, while ATO inhibits the activation of the PI3K-AKT pathway caused by MAPK inhibitors, thereby jointly inhibiting tumor growth.

As chemotherapy progresses, tumor cells gradually accumulate DNA damage under chemotherapy pressure, leading to a higher probability of gene mutations and clonal evolution associated with poor prognosis, increasing the likelihood of drug resistance; studies show that primary/acquired resistance in NB is also related to the high-frequency clonal diversity that gradually emerges with chemotherapy; under the selective pressure of chemotherapeutic drugs, cells with drug-resistant characteristics gradually expand and enrich, and gradually dominate; the later the remission time during induction chemotherapy in NB patients, the worse the prognosis; studies show that patients with initial bone marrow minimal residual disease(MRD) positivity who remain positive after 4 courses of chemotherapy have a significantly higher recurrence rate than those who become negative (74.1% vs. 33.3%), and the event-free survival has statistical significance; and radical surgery performed after the 3rd or 4th course of induction chemotherapy according to consensus and mainstream cooperative group regimens may also be one of the potential risk factors promoting the dissemination and metastasis of NB tumor cells; therefore, we chose to add trametinib to the medication sequence starting from the 5th course of induction chemotherapy, for a total of 5 courses of combined medication (the 5th to 9th courses of induction chemotherapy). The effectiveness and safety of the above combined medication strategy need to be further verified through multicenter collaborative clinical studies, and we expect that this combined medication regimen can improve the treatment status and prognosis of HR-NB, a refractory tumor.

Based on the above theoretical basis, the combination of MAPK pathway inhibitors with ATO has a synergistic effect, and we expect that the new regimen of adding the MAPK pathway inhibitor trametinib to the original ATO combined chemotherapy regimen can improve CRR. Therefore, this study aims to use the CRR at EOI of ATO combined chemotherapy and MAPK signaling pathway inhibitor(for example. trametinib) in the treatment of 4/M stage NB as the main research objective. The overall CRR at EOI for 4/M stage NB, both domestically and internationally, will serve as an external control to assess the clinical efficacy and safety of ATO-combined chemotherapy plus the MAPK signaling pathway inhibitor during the induction chemotherapy phase of 4/M stage NB.

Study Timeline

• Study First Submitted: 2025-02-07
• Status Verified: 2025-04
• Study First Submitted QC: 2025-04-15
• Last Update Submitted: 2025-04-15
• Study First Posted: 2025-04-18
• Last Update Posted: 2025-04-18
• Study Start: 2025-05-01
• Primary Completion: 2031-05-01
• Study Completion: 2031-05-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 92

Inclusion Criteria

1. Patients with a pathological diagnosis of neuroblastoma.
2. Preoperative staging as INRG M stage or postoperative staging as INSS stage 4 (regardless of risk classification).
3. Age ≥18 months and ≤18 years.
4. Informed consent obtained from the legal guardian, and signed informed consent form.

Exclusion Criteria

1. Patients with a history of other tumors who have received chemotherapy and abdominal radiation therapy.
2. Severe progressive or persistent heart failure: NYHA heart function class III or IV, or left ventricular ejection fraction (LVEF) < 50%.
3. Severe progressive or persistent renal failure: glomerular filtration rate (GFR) < 30 ml/(min·1.73 m²) or serum creatinine > 5 mg/dL (442 μmol/L).
4. Severe liver dysfunction: aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≥ 5× upper limit of normal (ULN), or serum total bilirubin ≥ 3× ULN.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Experiment group	Arsenic trioxide	-
Experiment group	MAPK inhibitors	-
Experiment group	Chemotherapy	-

Primary Outcome Measures

Name	Time	Method
Complete remission rate (CRR)	Four weeks after ATO-combined chemotherapy	Complete remission rate

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	Four weeks after ATO-combined chemotherapy	Objective Response Rate
Disease Free Survival	3 years	The proportion of patients who have not experienced recurrence of disease or death from any cause, whichever occurs first, within a maximum of 3 years from the date of enrollment.
Overall survival	3 years	The proportion of patients who are alive from the date of randomization to 3 years, regardless of the cause of death.
Incidence of Adverse Events	From the start of the combined regimen until the first documented adverse event, up to 3 years.	Incidence of Adverse Events

Trial Locations

Locations (1)

Sun Yat-sen Memorial Hospital; 🇨🇳 Guangzhou, Guangdong, China